The aim of case series is to describe the 3 Hemoglobin E ß-thalassemia cases, which are unique and requires special care and attention to diagnose/manage.Its natural history is little known, and also the reasons for their clinical diversity, or/and its management.
INTRODUCTION
The ß-thalassemia is an inherited blood disorder resulting in the synthesis of little or no ß-globin 1 chains of hemoglobin. Haemoglobin E-beta thalassemia (Hb E-ß-thalassemia) genotype is responsible for almost one-half of all severe betathalassemia worldwide. This blood disorder characterized by marked clinical variability from asymptomatic anemia to a life-threatening disorder, which requires blood transfusions from infancy life.
Hemoglobin E (HbE) is variant hemoglobin with a mutation in beta globin gene, which causes substitution of glutamic acid at position 26 for lysine in beta globin chain. HbE disease generally presents in 3 forms namely Heterozygous (Genotype AE or HbE trait), Homozygous (Genotype EE or Hb E disease) and Compound Heterozygous[Hb E Beta Thalassemia (E ß Thalassemia) & Sickle Cell / HbEdisease (SE 2 Genotype)] states. Haemoglobin E ß-thalassemia is the most common monogenic disorderin the Indian subcontinent. The average incidence of ß-thalassemia heterozygotes in India is about 4%, and about8,000-10,000 children with major disease are born annually. This contributes to about 10% of the total thalasse-1 micinfants born all over the world .
Case Series
Identification of this Hb variant thalassemia is very important, because doubly heterozygous state for HbE-ß-thalassemia is characterized clinically by thalassemia major. The clinical manifestations of Ebeta thalassemia generally include refractoryanemia, unexplained jaundice, splenomegaly, delayed puberty and stunted growth. In addition these patients may have complications like iron overload, hypercoagulable states particularly (postsplenectomy), and cardiopulmonary diseases. Thus the affected individual may besymptomatic and 3 transfusion dependent at an early age. However, repetitive transfusions cause iron overload, with life-threatening complications like cardiomyopathy, endocrine dysfunction, liver diseases and, ultimately, premature death. In the lack of red blood cell transfusion, patients with betathalassemia major die within the first five years of life. Beyond the age of 35 years, only 50-65% of patients live with transfusions in high-income 3 countries .It is very important to monitor the growth, quality of life, pubertal development, symptoms and signs of anemiain addition to 4 regimen of regular transfusion . The long-term clinical data and the phenotypic variability are the challenges for providing clinical recommendations in the management of patients. Recent research understanding reveals that, HbE thalassemia phenotype may be unstable, which may
PRESENTATION OF CASES
In this study, 3 cases of Hb E ß -thalassemia major have been included that were reported to the haematology department of the hospital during time period of two months. The inclusion criteria were children below 17 years of age with the diagnosis of transfusion dependent Hb E ß -thalassemia major. All the 3 patients belonged to West Bengal, India. The patients reported similar complaints of weakness and delayed milestones. One of them was currently admitted for elective splenectomy and the other two for bone marrow transplantation. The donor was full 10/10 match. One patient was symptomatic from the age of 2.5 years while the other two from the age of 3 years. Since then, they were receiving red blood cell transfusion and iron chelation therapy. The characteristics of the patients are discussed in Table 1 . reflect changes in adaptation to anemia and possibly due to attenuation of the erythropoietin response over time. This factor may make it difficult for the 5. development of broad treatment guidelines The Prognosis for individuals with this disease has been improved substantially in the recent decade with advances in blood transfusion, iron chelation therapy and transplantation of bone marrow. However, iron overload is the main cause for death 6 amongst this population . The cost of treatment of an 8-year-old thalassemic child is approximately about Rs.1 lakh annually. The only cure available today is bone marrow transplantation, which is largely unaffordable to the majority of the Indian children/parents. Most of these children have a severe clinical presentation but are managed sub-optimally due to lack of monetary resources in majority of the families. To combat the burden of hemoglobinopathies in India, there is an urgent need for the prenatal diagnosis of thalassemia. The important prerequisite for this disorder is to create awareness on the prevalence of ß-thalassemia in different ethnic groups and in different regions of the country. Education and screening plays the most important part for the success of prevention programs for the control of thalassemia.
CONCLUSION

